Literature DB >> 2465551

Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens.

I Keydar1, C S Chou, M Hareuveni, I Tsarfaty, E Sahar, G Selzer, S Chaitchik, A Hizi.   

Abstract

We have generated a mouse monoclonal antibody (H23) against the retrovirus-like particles (human mammary tumor virus) released in vitro by the human breast adenocarcinoma cell line T47D. This antibody reacts specifically with a glycoprotein with an apparent molecular mass of 68 kDa (gp68) that is detected in the growth medium of T47D cells as well as in pleural effusion fluids from breast adenocarcinoma patients. No detectable levels of this antigen could be observed in pleural effusions of patients with cancers other than of breast origin. The H23-related antigen was localized in the cytoplasm of breast tumor cells as well as on the cell surface of both T47D cells and metastatic cells from breast cancer patients. A survey of tissue from 812 patients was performed by using H23 in an indirect immunoperoxidase assay. The results showed that the antigen was detectable in 91% of all breast tumors tested. No cytoplasmic staining was observed in either normal tissues or nonbreast carcinomas. Only one of the benign breast tissues tested (out of a total of 56 samples of tissue) was positive for this antigen. Given the ability of this antibody to specifically detect breast tumor cells, H23 may be of importance in diagnosis and in clinical follow-up of patients for the detection of metastatic lesions by imaging and for therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2465551      PMCID: PMC286690          DOI: 10.1073/pnas.86.4.1362

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Establishment and characterization of a cell line of human breast carcinoma origin.

Authors:  I Keydar; L Chen; S Karby; F R Weiss; J Delarea; M Radu; S Chaitcik; H J Brenner
Journal:  Eur J Cancer       Date:  1979-05       Impact factor: 9.162

3.  Prognostic factors in breast cancer--a pathological and immunological study of patients with stage 1 breast cancer.

Authors:  S Chaitchik; B Kabakow; A De Chabon; J J Jonson; A Bar-Eyal; G Selzer; E J Feuer; I Keydar; A Hizi
Journal:  Eur J Surg Oncol       Date:  1987-12       Impact factor: 4.424

4.  Particles with properties of retroviruses in monocytes from patients with breast cancer.

Authors:  A M Al-Sumidaie; S J Leinster; C A Hart; C D Green; K McCarthy
Journal:  Lancet       Date:  1988 Jan 2-9       Impact factor: 79.321

5.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.

Authors:  E Engvall; P Perlmann
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

Review 6.  Monoclonal antibodies and breast cancer.

Authors:  A Thor; M O Weeks; J Schlom
Journal:  Semin Oncol       Date:  1986-12       Impact factor: 4.929

Review 7.  Mammary tumor viruses.

Authors:  D H Moore; C A Long; A B Vaidya; J B Sheffield; A S Dion; E Y Lasfargues
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

8.  The surgeon's role in breast cancer: changing concepts.

Authors:  H P Leis
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

9.  A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations.

Authors:  M Nuti; Y A Teramoto; R Mariani-Costantini; P H Hand; D Colcher; J Schlom
Journal:  Int J Cancer       Date:  1982-05-15       Impact factor: 7.396

10.  Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3.

Authors:  A Thor; N Ohuchi; C A Szpak; W W Johnston; J Schlom
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

View more
  8 in total

1.  Negative regulation of the endocytic adaptor disabled-2 (Dab2) in mitosis.

Authors:  David Chetrit; Lior Barzilay; Galit Horn; Tom Bielik; Nechama I Smorodinsky; Marcelo Ehrlich
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

2.  Autoantibodies against the signal peptide domain of MUC1 in patients with multiple myeloma: Implications for disease diagnosis and prognosis.

Authors:  Riva Kovjazin; Anna Dubnik; Galit Horn; Nechama I Smorodinsky; Izhar Hardan; Michael Yechiel Shapira; Lior Carmon
Journal:  Exp Ther Med       Date:  2012-04-03       Impact factor: 2.447

3.  Vaccination against tumor cells expressing breast cancer epithelial tumor antigen.

Authors:  M Hareuveni; C Gautier; M P Kieny; D Wreschner; P Chambon; R Lathe
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

4.  Human immunodeficiency virus type 1-like DNA sequences and immunoreactive viral particles with unique association with breast cancer.

Authors:  E M Rakowicz-Szulczynska; B Jackson; A M Szulczynska; M Smith
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

5.  Purification and characterisation of a breast-cancer-associated glycoprotein not expressed in normal breast and identified by monoclonal antibody 83D4.

Authors:  G Pancino; E Osinaga; C Charpin; D Mistro; J P Barque; A Roseto
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

6.  An evaluation of the putative human mammary tumour retrovirus associated with peripheral blood monocytes.

Authors:  L P Kahl; A R Carroll; P Rhodes; J Wood; N G Read
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

7.  Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy.

Authors:  Riva Kovjazin; Galit Horn; Nechama I Smorodinsky; Michael Y Shapira; Lior Carmon
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

8.  Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2.

Authors:  Susy Scholl; Patrick Squiban; Nadine Bizouarne; Martine Baudin; Bruce Acres; Silvia Von Mensdorff-Pouilly; Moira Shearer; Philippe Beuzeboc; S. Van Belle; B. Uzielly; Pierre Pouillart; Joyce Taylor-Papadimitriou; David Miles
Journal:  J Biomed Biotechnol       Date:  2003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.